Another dataset of NSCLC patients (GSE126044) who were also treated by anti-PD-1/PD-L1 immunotherapy showed that the PRSs of those who responded to immunotherapy were significantly lower than those who did not respond (Wilcoxon test, p < 0.05, Supplementary Figure S8B). Here, CD274 is linked to non-small cell lung carcinoma.